Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Modest growth for Astellas in challenging quarter

This article was originally published in Scrip

Executive Summary

Astellasmight have warned about a tough year ahead at the time its year-end results were announced in May, but all things considered the company got off to a reasonable start in the first quarter, overcoming currency losses and the April price cut in Japan to post modest overall growth. But some new questions have appeared over the development of its Factor Xa inhibitor YM150.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts